VivoSeq
Other

Analgesic

0

Pipeline Programs

13

Active Trials

6

Companies Involved

Analgesic is an early-stage landscape with 0 programs across 6 companies. The most active players are Pfizer, Bayer, Cara Therapeutics, Inc..

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

17/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

89

clinical trials

Completed54 · 61%
Terminated9 · 10%
Unknown status7 · 8%
Recruiting6 · 7%
Withdrawn6 · 7%
Active, not recruiting3 · 3%
Other4 · 4%

Trial Activity

89 trials

Post-operative Analgesic Effect of Oral Nefopam
Recruiting·HHospices Civils de Lyon·Phase 2·NCT04576078·40 enrolled
Anesthetics and Analgesics in Children
Recruiting··N/A·NCT03427736·460 enrolled
Analgesic and Subjective Effects of Terpenes
Active, not recruiting·UUniversity of California, Los Angeles·Phase 1·NCT04451863·45 enrolled
Opioid Analgesic Reduction Study
Active, not recruiting·RRutgers, The State University of New Jersey·Phase 3·NCT04452344·1,815 enrolled
Analgesic and Anti-inflamatory Effect of Vit. B
Not yet recruiting··N/A·NCT06857734·90 enrolled
EMLA Cream as Analgesic for Outpatient Gynecological Procedures
Enrolling by invitation··Phase 4·NCT05970354·400 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)